«We are cautiously optimistic that any impact
of levofloxacin on antibacterial resistance will be balanced by the reduction in use of other antibiotics, but long - term monitoring antibiotic resistance patterns in young ALL patients will be needed to prove this,» Wolf said.
Meanwhile, antibiotic resistance did not significantly increase despite greater use
of levofloxacin to prevent infections.
Not exact matches
Researchers reported that preventive therapy with
levofloxacin or other antibiotics reduced the odds
of infection, including fevers and bloodstream infections, by 70 percent or more in ALL patients with neutropenia during induction therapy.
Researchers said the reduced exposure might explain why
levofloxacin reduced odds
of infection with C difficile.
Levofloxacin also reduced patients» odds
of antibiotic - associated infection with Clostridium difficile by 95 percent or more.
On February 8, 2018, Canada's Federal Court
of Appeal (FCA) dismissed Teva Canada Limited's consolidated appeals from a Federal Court (FC) decision ordering Teva to pay damages to Janssen Canada and Janssen US for infringement
of Canadian Patent No 1,304,080 (the «080 Patent) claiming
levofloxacin (Janssen's LEVAQUIN ®)(Teva Canada Limited v Janssen Inc, 2018 FCA 33, aff» g 2016 FC 593).